US Patent

US11497745 — Methods for treating cholestasis

Method of Use · Assigned to Mirum Pharmaceuticals Inc · Expires 2040-02-12 · 14y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for treating cholestasis in a subject with liver disease by administering at least 10 Î¼g/kg/day of an Apical Sodium-dependent Bile Acid Transporter (ASBTI).

USPTO Abstract

Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 Î¼g/kg/day.

Drugs covered by this patent

maralixibat-chloride (MARALIXIBAT CHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3974`	—	maralixibat-chloride
`U-4187`	—	maralixibat-chloride
`U-4187`	—	maralixibat-chloride
`U-4187`	—	maralixibat-chloride
`U-4187`	—	maralixibat-chloride

Patent Metadata

Patent number: US11497745
Jurisdiction: US
Classification: Method of Use
Expires: 2040-02-12
Drug substance claim: No
Drug product claim: No
Assignee: Mirum Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.